ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly.

Détails

Ressource 1Télécharger: 35615412_BIB_F8F78DB93C6E.pdf (980.63 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_F8F78DB93C6E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly.
Périodique
ERJ open research
Auteur⸱e⸱s
Lichtblau M., Piccari L., Ramjug S., Bokan A., Lechartier B., Jutant E.M., Barata M., Garcia A.R., Howard L.S., Adir Y., Delcroix M., Jara-Palomares L., Bertoletti L., Sitbon O., Ulrich S., Vonk Noordegraaf A.
ISSN
2312-0541 (Print)
ISSN-L
2312-0541
Statut éditorial
Publié
Date de publication
04/2022
Peer-reviewed
Oui
Volume
8
Numéro
2
Pages
00665-2021
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro-con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/06/2022 14:27
Dernière modification de la notice
25/01/2024 8:47
Données d'usage